AnaptysBio files lawsuit against Tesaro over collaboration breach
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Cerebras Systems falls as TD Cowen cuts price target
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- Marvell Technology shares rise on analyst support
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
November 21, 2025 3:50 AM ESTSAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. (Tesaro) has materially breached the parties Collaboration and Exclusive License Agreement (Collaboration Agreement) and that GSK (Tesaros corporate parent) has tortiously interfered with the Collaboration Agreement. Anaptys has requested that the court declare that Anaptys is entitled to all rights and remedies under the Collaboration Agreement.
The Complaint contends that Tesaro breached, and GSK induced Tesaro to breach,... More



